| Bronvermelding: | -TDM monografie haloperidol NVZA
-Hiemke et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. :harmacospychiatry 44:195-235
-Bjørndal N , Bjerre M , Gerlach J et al. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side eff ects, serum haloperidol, and serum prolactin . Psychopharmacology (Berl) 1980 ; 67 : 17 – 23
-Fitzgerald P B , Kapur S , Remington G et al. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels . Psychopharmacology (Berl) 2000 ; 149 : 1 – 5
-Nyberg S , Nordström A L , Halldin C et al. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man . Int Clin Psychopharmacol 1995 ; 10 (Suppl 3 ): 81 – 85
-Panagiotidis G , Arthur H W , Lindh J D et al. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther Drug Monit 2007 ; 29 : 417 – 422
-Perry P J , Miller D D , Arndt S V et al. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics . J Clin Psychopharmacol 1993 ; 13 : 46 – 51
-Ulrich S , Wurthmann C , Brosz M et al. The relationship between serum concentration and therapeutic eff ect of haloperidol in patients with acute schizophrenia . Clin Pharmacokinet 1998 ; 34 : 227 – 263
-Van Putten T , Marder S R , Wirshing W C et al. Neuroleptic plasma levels. Schizophr Bull 1991 ; 17 : 197 – 216 |
